微小病变肾病的发病机制及治疗研究进展  

Progress of research on minimal change disease in its pathogenesis and treatment

作　　者：赵静 张嘉欣 高言 谢席胜[1,2,3] Jing Zhao;Jiaxin Zhang;Yan Gao;Xisheng Xie(Department of Nephrology,Nanchong Central Hospital Affiliated to North Sichuan Medical College 2.Department of Nephrology,Nanchong Central Hospital Affiliated to North Sichuan Medical College;Nanchong Key Laboratory of Basic&Clinical Research on Chronic Kidney Disease;Nanchong Clinical Medical Research Center,Nanchong 637000,Sichuan Province,China)

机构地区：[1]川北医学院附属南充市中心医院肾内科,637000 [2]南充市慢性肾脏病基础与临床研究重点实验室,637000 [3]南充市临床医学研究中心,637000

出　　处：《中华肾病研究电子杂志》2024年第4期207-212,共6页Chinese Journal of Kidney Disease Investigation（Electronic Edition）

基　　金：四川省中医药管理局中医药科研专项(2020JC079);四川省科技厅专项基金(2021YFS0259);南充市科技局计划项目(22JCYJPT0005)。

摘　　要：微小病变肾病(MCD)是成人原发性肾病综合征的常见病因,发病机制尚未完全明了。目前MCD主要治疗用药依然是糖皮质激素和免疫抑制剂,其副作用和疾病高复发率备受关注。本文综述了MCD流行病学、发病机制、传统激素和免疫抑制剂治疗、生物制剂及靶向药物治疗方面的研究进展。Minimal change disease (MCD) is a common cause of adult primary nephrotic syndrome, yet its pathogenesis has not been completely understood yet. At present, the main treatment drugs for MCD are glucocorticoids and immunosuppressants, and their side effects and high recurrence rate of disease have received much attention. This article reviewed the epidemiology, pathogenesis, traditional glucocorticoids and immunosuppressants therapy, biologics and targeted drug therapy of MCD.

关 键 词：微小病变肾病 发病机制 治疗 

分 类 号：R692[医药卫生—泌尿科学]